Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
Holding BEAM?
Track your performance easily
BEAM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.84 - $49.50
Previous Close$24.05
Volume2.26M
Average Volume (3M)940.52K
Market Cap
$1.99B
Enterprise Value$1.23B
Total Cash (Recent Filing)$925.76M
Total Debt (Recent Filing)$162.06M
Price to Earnings (P/E)―
Beta2.63
Next Earnings
Mar 04, 2025EPS Estimate
-$1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding82,805,627
10 Day Avg. Volume1,535,433
30 Day Avg. Volume940,517
Standard Deviation0.26
R-Squared0.14
Alpha0.00367
Financial Highlights & Ratios
Price to Book (P/B)2.52
Price to Sales (P/S)6.23
Price to Cash Flow (P/CF)-6.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.51
Enterprise Value/Gross Profit3.25
Enterprise Value/Ebitda-8.56
Forecast
1Y Price Target
$47.67Price Target Upside98.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Beam Therapeutics News
Bulls Say, Bears Say
Bulls Say
Innovation In Genetic MedicineBeam's base editing platform may overcome limitations of existing approaches and expand the potential of genetic medicines.
Market PotentialESCAPE has the potential to expand the treatable SCD patient population by 3-fold, up to 30,000 SCD patients in the U.S.
Therapeutic AdvancementsBEAM-101 shows a potentially differentiated therapeutic profile for sickle cell disease, with higher fetal hemoglobin levels and lower sickle cell hemoglobin levels.
Bears Say
Clinical TrialsBeam's first clinical efficacy data in four sickle cell disease patients got marred with one patient death due to respiratory failure, likely related to busulfan conditioning regimen.
Market PositionBeam Therapeutics is expected to be the third player in gene editing for sickle cell disease, trailing behind Vertex and Editas.
Valuation ConcernsBeam Therapeutics is trading at a high implied enterprise value compared to peers without presenting any clinical data, raising concerns about overvaluation.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $20.84 and its highest was $49.50 in the past 12 months.
What is Beam Therapeutics’s market cap?
Currently, no data Available
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 107 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Nov 05, 2024. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.183 by $0.013.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics does not currently pay dividends.
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -$1.25.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 82,805,626 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.183. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Among the largest hedge funds holding Beam Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Beam Therapeutics’s shares valued at 194M.
---
Beam Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.67 (98.21% Upside)
$47.67 (98.21% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.37%
12-Months-Change
Fundamentals
Return on Equity
-18.29%
Trailing 12-Months
Asset Growth
-9.23%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
---
BEAM Earnings Call
Q3 2024
0:00 / 0:00
---
BEAM Stock 12 Month Forecast
Average Price Target
$47.67
▲(98.21% Upside)
Technical Analysis
Intellia Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Best Analysts Covering BEAM
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
-0.80%
assigned a buy rating 5 months ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of -0.80% per trade.
---